Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced validation for the European patent 2019213664 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL” in the United Kingdom, Italy, Germany, France, and Spain. This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid until 2039.
Related news for (PBLA)
- Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
- Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Panbela Announces Closing of Approximately $9.0 Million Public Offering
- Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
- Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)